

Venture Mega-Rounds Come Back to Biotech..... 2

THE WALL STREET JOURNAL.

Venture Mega-Rounds Come Back to Biotech

By Brian Gormley

691 words

27 September 2024

The Wall Street Journal

J

B8

English

Copyright 2024 Dow Jones & Company, Inc. All Rights Reserved.

Venture mega-rounds are on the rise in biotechnology as the outlook for the industry brightens.

Sixty-eight U.S. and European biotech startups raised venture financings of \$100 million or more this year through Aug. 31, putting this year on track to at least approach the 106 mega-rounds closed in 2021, the highest number on record, according to Silicon Valley Bank.

Venture capitalists are increasingly confident that biotech is stabilizing after two years in which valuations reset lower from their 2021 highs. Mega-rounds also reflect a flight to quality, as investors crowd around what they view as the strongest companies, some observers said.

"We're seeing investors really focus on quality over quantity," said Jackie Spencer, head of U.S. relationship management, life science and healthcare for SVB.

Mega-rounds are becoming common, even though fewer deals are getting done and less venture capital is going into biotech. Venture investors put \$15.3 billion into 351 biotech financings in this year's first half, compared with \$36.6 billion through 845 rounds in all of 2021, according to SVB.

Giant financings help startups propel medicines through clinical trials and buffer them against setbacks. And they reduce one of the biggest risks in biotech: that a company will run out of cash before its drug shows potential.

To be sure, mega-rounds can lead to trouble if a startup blows through its newfound capital. Investors will often push for financings to be meted out in tranches to protect themselves in just such cases.

Reunion Neuroscience, a Morristown, N.J.-based company targeting psychedelic drugs for mental-health disorders, recently raised a \$103 million Series A round in three tranches, with roughly one-third coming up front, about one-third awarded for reaching milestones in its mid-stage, or Phase 2, clinical trial, and the rest if the trial yields positive results, Chief Executive Greg Mayes said.

"It's a way to pay for performance and requires that the companies remain disciplined," Mayes added.

Mega-deals this year also differ from those closed in 2021 in that they come together more slowly. Back then, it might have taken only weeks; these days, the pace is more measured. Because competition for deals has eased, investors have more time to evaluate startups and are finding several with compelling data and reasonable valuations, observers said.

"Investors are discriminating more today," said Stephanie Sirota, partner and chief business officer of life-sciences investor RTW Investments. "The diligence that is happening today feels like it is more rigorous."

Boston-based Superluminal Medicines, which applies **machine-learning**, chemistry and other capabilities to drug discovery, raised a \$120 million Series A round of financing earlier this month after collecting \$33 million in seed funding last year.

The company, which develops oral treatments for metabolic diseases and other conditions, used its seed financing and **technology** to create six drug programs. That helped catalyze this latest round, an infusion that will enable the company to put its first drug into clinical trials and advance other compounds, CEO Cony D'Cruz said.


When raising funds, biotechs typically aim to secure enough capital to gather clinical data and support themselves for a year or more after, which gives them time to assess their next move. Startups raising large sums need specific plans for deploying the capital and avoid veering off course, some investors said.

"Having access to more capital does not necessarily mean it needs to be spent on more things," said Dr. Aaron Royston, a managing partner with biotech investor venBio. "Focus is really important."

Startups raising mega-rounds at high valuations also can face pressure to grow into it -- and the prospect that their next financing will be done at a lower price if they don't succeed.

"It can be a killer if you take a high valuation and then the next round you have to do a down round. The whole psyche of your investors goes sour," said Cheryl Reicin, partner and international chair of life sciences for law firm Mintz Levin Cohn Ferris Glovsky and Popeo.

Number of biotech
venture-capital financings in
the U.S. and Europe*



*Of \$100 million or more; 2024 figure is through Aug. 31.
Source: Silicon Valley Bank

Document J000000020240927ek9r00036

Search Summary

Text	(technology OR "AI" OR fintech OR "digital banking" OR "cloud computing" OR blockchain OR cybersecurity OR "machine learning" OR "data analytics" OR "big data" OR "predictive analytics" OR "cloud migration" OR "edge computing" OR "5G banking" OR "API banking" OR "open banking" OR "data governance" OR "data monetization" OR "digital transformation" OR "quantum computing" OR "AI-driven banking" OR "AI in compliance" OR "AI-powered fraud detection" OR "AI in customer service" OR "AI in investment banking" OR "conversational AI" OR "generative AI" OR "robo-advisors" OR "natural language processing" OR "algorithmic trading" OR "automated risk assessment" OR "AI regulatory challenges" OR "embedded finance" OR neobanks OR "Banking as a Service" OR "BaaS" OR regtech OR supotech OR "decentralized finance" OR DeFi OR "cryptocurrency adoption" OR "Central Bank Digital Currencies" OR CBDCs OR tokenization OR "real-time payments" OR "Buy Now Pay Later" OR BNPL OR "cyber resilience" OR "Zero Trust security" OR "identity verification" OR "fraud detection" OR "insider threats" OR "AI-driven cybersecurity" OR "financial data breaches" OR "data privacy laws" OR GDPR OR CCPA OR "operational risk
------	---

	management" OR "regulatory compliance technology" OR KYC OR "Know Your Customer" OR AML OR "Anti-Money Laundering" OR "hyper-personalization in banking" OR "customer-centric banking" OR "omnichannel banking" OR "digital wallets" OR "contactless payments" OR "voice banking" OR "biometric authentication" OR "wearable banking" OR "banking UX/UI innovations" OR "financial inclusion technology")
Date	07/01/2024 to 09/30/2024
Source	The New York Times Or The Wall Street Journal Or The Economist Or Forbes
Author	All Authors
Company	First Citizens Bancshares Inc
Subject	All Subjects
Industry	All Industries
Region	All Regions
Language	English
Results Found	1
Timestamp	17 March 2025 8:42 PM GMT